Why did Elevance's profitability decline so sharply in Q4 2024?

The main driver was a 320 basis point increase in the benefit expense ratio to 92.4%, caused mainly by higher Medicaid medical cost trends related to membership redeterminations. Health Benefits operating gain fell to $0.2 billion from $0.8 billion. Operating expense efficiency improved, with the adjusted operating expense ratio down 170 basis points to 9.9%, but this did not offset the medical cost pressure.

Is Elevance's dividend at risk given the earnings decline?

The dividend appears well covered by earnings but less so by cash flow in 2024. The company raised its quarterly dividend 5% to $1.71 per share. Dividends paid in 2024 totaled $1.5 billion against $5.8 billion of operating cash flow, and the company guided to about $8.0 billion of operating cash flow in 2025. The parent company held approximately $2.4 billion in cash and investments at year-end 2024. Investors should still monitor cash generation, since 2024 operating cash flow fell from $8.1 billion and the company also spent $4.4 billion on acquisitions and $2.9 billion on buybacks.

How is Elevance's balance sheet and leverage changing?

Leverage increased during 2024. Long-term debt, net of the current portion, rose to $29.2 billion from $23.2 billion, and net borrowings were $6.2 billion for the year. Total shareholders' equity increased to $41.3 billion from $39.3 billion. Goodwill and other intangible assets grew to $40.4 billion from $35.6 billion, largely from acquisitions. Interest expense rose 15% to $1.2 billion, and 2025 guidance projects it will increase further to $1.5 billion, which will weigh on pre-tax income.

Which business segment is driving growth, and which is under pressure?

Carelon is the growth engine. Its Q4 revenue rose 19% to $14.7 billion and full-year revenue rose 12% to $53.9 billion, supported by risk-based capabilities in Carelon Services and acquisitions. CarelonRx grew Q4 revenue 13% to $10.0 billion. Health Benefits is under pressure: revenue grew only 1% for the year, operating margin fell to 4.2% from 4.6%, and Q4 margin was 0.6%. Medicaid is the core problem, as its membership declined 15% and cost trends rose. Carelon Services Q4 operating margin also fell to 0.7% from 2.9%, which investors should monitor closely.

ELV 8-K: Earnings & Results

Q: What does Elevance's 2025 guidance imply for earnings?

Management guided to adjusted diluted EPS of $34.15 to $34.85, which is roughly flat to slightly higher than 2024's $33.04. GAAP EPS is guided to $30.40 to $31.10, compared with $25.68 in 2024. The guidance assumes a benefit expense ratio of 89.1% plus or minus 50 basis points, which is higher than 2024's 88.5%, so margin recovery depends on Carelon and CarelonRx growth and on operating expense reductions. Diluted shares are expected to fall to 225 to 226 million from 232.9 million.

01—Abstract

Summary

Summary of the 8-K filed January 23, 2025. Cited figures are marked; the original filing is the authoritative source.

Elevance Health (ELV) reported fourth quarter 2024 results that fell well short of prior-year profitability, driven by Medicaid cost pressures, while full-year revenue still grew.

Q4 operating revenue rose 6% to $45.0 billion^a and full-year revenue rose 3% to $175.2 billion, supported by higher premium yields, 2024 acquisitions, and growth in CarelonRx and Carelon Services. However, the benefit expense ratio rose 320 basis points to 92.4% in Q4 and 150 basis points to 88.5% for the year, mainly from higher Medicaid medical cost trends tied to eligibility redeterminations. Q4 GAAP diluted EPS was $1.81 versus $3.63 a year earlier, and adjusted EPS was $3.84 versus $5.62.

Full-year GAAP diluted EPS was $25.68^b and adjusted EPS was $33.04, down 0.3% from $33.14. Health Benefits operating gain fell 73% in Q4 to $0.2 billion, while Carelon's adjusted operating gain grew 32% in the quarter. Management guided to 2025 adjusted diluted EPS of $34.15 to $34.85 and GAAP EPS of $30.40 to $31.10.

The adjusted operating gain outlook of $9.55 to $9.85 billion^c implies growth from the 2024 level of $9.3 billion. Guidance assumes a benefit expense ratio of 89.1% (plus or minus 50 basis points), total operating revenue growth in the high single to low double digits, and operating cash flow of about $8.0 billion. Medicaid membership is expected to decline further to 8.6 to 8.9 million.

The company also raised its quarterly dividend 5% to $1.71^d per share and retains about $9.3 billion of share repurchase authorization. The key investor question is whether Medicaid cost trends stabilize and whether the 2025 margin recovery is achievable. Full-year operating cash flow of $5.8 billion fell from $8.1 billion in 2023, and cash flow conversion was about 1.0 times GAAP net income.

Total debt rose meaningfully during the year, with long-term debt increasing to $29.2 billion from $23.2 billion, which reflects acquisition funding. Investors will likely focus on medical cost trend execution, the pace of Carelon growth, and free cash flow generation relative to the dividend and buybacks.

02—Key points

Key Highlights

Q4 2024 operating revenue of $45.0 billion rose 6% year over year; full-year revenue of $175.2 billion rose 3%, driven by premium yields, acquisitions, and CarelonRx product revenue.
Benefit expense ratio rose to 92.4% in Q4 (+320 bps) and 88.5% for the full year (+150 bps), primarily from higher Medicaid medical cost trends.
Q4 GAAP diluted EPS was $1.81 (down from $3.63) and adjusted EPS was $3.84 (down from $5.62); full-year GAAP EPS was $25.68 and adjusted EPS was $33.04, roughly flat.
Health Benefits Q4 operating gain fell 73% to $0.2 billion, while Carelon's adjusted Q4 operating gain rose 32% to $0.8 billion on higher pharmacy product revenue.
2025 guidance: adjusted diluted EPS of $34.15 to $34.85, GAAP EPS of $30.40 to $31.10, adjusted operating gain of $9.55 to $9.85 billion, and operating cash flow of about $8.0 billion.
Medical membership fell 2.3% to 45.7 million, with Medicaid down 15.1%; 2025 guidance expects total medical enrollment of 45.75 to 46.6 million, with Medicaid declining further.
Quarterly dividend raised 5% to $1.71 per share; about $9.3 billion of share repurchase authorization remained at year-end, and Q4 buybacks totaled $1.8 billion.

03—Questions

Frequently Asked Questions

Why did Elevance's profitability decline so sharply in Q4 2024?
The main driver was a 320 basis point increase in the benefit expense ratio to 92.4%, caused mainly by higher Medicaid medical cost trends related to membership redeterminations. Health Benefits operating gain fell to $0.2 billion from $0.8 billion. Operating expense efficiency improved, with the adjusted operating expense ratio down 170 basis points to 9.9%, but this did not offset the medical cost pressure.
What does Elevance's 2025 guidance imply for earnings?
Management guided to adjusted diluted EPS of $34.15 to $34.85, which is roughly flat to slightly higher than 2024's $33.04. GAAP EPS is guided to $30.40 to $31.10, compared with $25.68 in 2024. The guidance assumes a benefit expense ratio of 89.1% plus or minus 50 basis points, which is higher than 2024's 88.5%, so margin recovery depends on Carelon and CarelonRx growth and on operating expense reductions. Diluted shares are expected to fall to 225 to 226 million from 232.9 million.
Is Elevance's dividend at risk given the earnings decline?
The dividend appears well covered by earnings but less so by cash flow in 2024. The company raised its quarterly dividend 5% to $1.71 per share. Dividends paid in 2024 totaled $1.5 billion against $5.8 billion of operating cash flow, and the company guided to about $8.0 billion of operating cash flow in 2025. The parent company held approximately $2.4 billion in cash and investments at year-end 2024. Investors should still monitor cash generation, since 2024 operating cash flow fell from $8.1 billion and the company also spent $4.4 billion on acquisitions and $2.9 billion on buybacks.
How is Elevance's balance sheet and leverage changing?
Leverage increased during 2024. Long-term debt, net of the current portion, rose to $29.2 billion from $23.2 billion, and net borrowings were $6.2 billion for the year. Total shareholders' equity increased to $41.3 billion from $39.3 billion. Goodwill and other intangible assets grew to $40.4 billion from $35.6 billion, largely from acquisitions. Interest expense rose 15% to $1.2 billion, and 2025 guidance projects it will increase further to $1.5 billion, which will weigh on pre-tax income.
Which business segment is driving growth, and which is under pressure?
Carelon is the growth engine. Its Q4 revenue rose 19% to $14.7 billion and full-year revenue rose 12% to $53.9 billion, supported by risk-based capabilities in Carelon Services and acquisitions. CarelonRx grew Q4 revenue 13% to $10.0 billion. Health Benefits is under pressure: revenue grew only 1% for the year, operating margin fell to 4.2% from 4.6%, and Q4 margin was 0.6%. Medicaid is the core problem, as its membership declined 15% and cost trends rose. Carelon Services Q4 operating margin also fell to 0.7% from 2.9%, which investors should monitor closely.

04—Continue

← View all 8-K filings